Cogent Biosciences, Inc. (COGT) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 8 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Mon, Aug 10, 2026before open 41 8-K
Q1 FY2026Tue, May 5, 2026before open 35 8-K
Q4 FY2025Tue, Feb 17, 2026before open 48 8-K
Q3 FY2025Mon, Nov 3, 2025before open 34 8-K
Q2 FY2025Tue, Aug 5, 2025before open 36 8-K
Q1 FY2025Tue, May 6, 2025before open 36 8-K
Q4 FY2024Tue, Feb 25, 2025before open 56 8-K

What they guided beta

Q3 FY2026 "Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of $791.1 million expected to fund operations into late 2028 WALTHAM, Mass. and BOULDER, Colo., November 5, 2026 – Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and " exhibit
Q3 FY2026 "The company believes that its cash, cash equiv alents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib." exhibit
Q2 FY2026 "SUMMIT extension trial with preliminary results expected by end of 2026." exhibit
Q2 FY2026 "T he company expects its existing cash, cash equivalents and marketable securities, with the $73.6 million gross proceeds from shares sold through the Company’s at-the-market (ATM) facility after the end of the quarter, will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028, including through potential FDA approvals of bezuclastinib for GIST, NonAdvSM and AdvSM and early commercial launch activities." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/COGT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/COGT

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

COGT earnings date badge

HTML

<a href="https://veritasdata.dev/company/COGT/"><img src="https://veritasdata.dev/embed/COGT.svg" alt="COGT earnings date" width="240" height="56"></a>

Markdown

[![COGT earnings date](https://veritasdata.dev/embed/COGT.svg)](https://veritasdata.dev/company/COGT/)

Script

<script async src="https://veritasdata.dev/embed/COGT.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/COGT"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.